StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report sent to investors on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Down 0.5 %
Pulmatrix stock opened at $2.02 on Thursday. The stock has a market cap of $7.38 million, a P/E ratio of -0.84 and a beta of 1.00. The stock has a 50 day moving average of $2.08 and a 200-day moving average of $2.02. Pulmatrix has a 52 week low of $1.55 and a 52 week high of $2.75.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The firm had revenue of $1.55 million for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- Roth IRA Calculator: Calculate Your Potential Returns
- Is Spotify Stock Poised to Soar? Options Traders Think So
- When to Sell a Stock for Profit or Loss
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Dividend Payout Ratio Calculator
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
